Neuro-Oncology News

The FDA granted fast track designation to TVI-Brain-1, an adoptive T cell therapy for the treatment of glioblastoma multiforme, according to the agent’s manufacturer.

Chimeric antigen receptor T-cell therapies have demonstrated limited antitumor activity in glioblastoma. Although the therapies have been tolerable, response rates have been low and responses lack durability.

Risk for suicide appeared higher among individuals within the first year of a brain cancer diagnosis compared with the general population, according to a research letter published in JAMA Network Open.

National Brain Tumor Awareness Month is commemorated in May.

Routine surveillance imaging after surgery did not appear to improve outcomes among patients with glioblastoma, according to study results published in World Neurosurgery.

The investigational MET inhibitor capmatinib appeared effective for treatment of certain patients with metastatic non-small cell lung cancer, including those with brain metastases, according to cohort analyses of the phase 2 GEOMETRY mono-1 study presented at the virtual American Association for Cancer Research Annual Meeting.

Hippocampal avoidance during whole-brain radiotherapy with memantine for brain metastases appeared to better preserve cognitive function and improve patient-reported outcomes, according to results of a randomized phase 3 study published in Journal of Clinical Oncology.

Substantial improvements in cancer treatment during the past several decades are an unequivocal victory for oncology — making long-term survival a reality for many patients.

The FDA granted fast track designation to tozuleristide for treatment of pediatric central nervous system tumors.

Parker Institute for Cancer Immunotherapy awarded up to $2.75 million in grant funding to six early career researchers.